Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026)

Revolution Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $87.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 248.03% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $151.6 million (up 671.05% YoY), while the FY2025 annual figure was $208.4 million, up 75.42% from the prior year.
• Share-based Compensation for Q1 2026 stood at $87.3 million, down from $95.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $178.5 million in Q2 2025, with the low at -$56.8 million in Q4 2024.
• The 5-year median for Share-based Compensation is $13.7 million (2023), against an average of $46.4 million.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 469.21% in 2022, then soared 814.48% in 2024.
• Revolution Medicines' Share-based Compensation stood at -$22.9 million in 2022, then jumped by 51.6% to -$11.1 million in 2023, then sank by 412.53% to -$56.8 million in 2024, then surged by 269.02% to $95.9 million in 2025, then fell by 9.0% to $87.3 million in 2026.
• Business Quant data shows RVMD's Share-based Compensation at $87.3 million in Q1 2026, $95.9 million in Q4 2025, and $177.7 million in Q3 2025.